A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants with Early-Stage Parkinson’s Disease

Condition studied

Parkinson’s Disease (PD)

Investigational medicinal product(s)

Every trial of RO7568282 across our registers →

Eligibility

Primary endpoint

Time to a confirmed motor progression event from the randomization date (assessed in off medication state).

Endpoint detail

Change in motor signs from baseline at week 104, as measured by the MDS-UPDRS Part III score (assessed in off medication state), Time to worsening of participants’ motor function as reported by the participant in the presence of a confirmed motor progression event., The incidence, severity, seriousness, and causal relationship of adverse events (AEs)s, The incidence of abnormal laboratory findings in blood and urine, The incidence of abnormal vital signs and electrocardiogram (ECG) parameters, The change in Columbia-Suicide Severity Rating Scale (C-SSRS) from baseline, Plasma concentrations or pharmacokinetic (PK) parameters of RO7568282 (and its metabolite(s) as appropriate)